BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects

Pancreatic ductal adenocarcinoma (PDAC) remains a challenging disease to treat. Despite advances in surgical techniques, radiation, and medical therapies, the 5-year survival rate remains below 9%. Over the past decade, the genomic landscape of PDAC has been well studied and BRCA mutations have emer...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Winston, Raufi, Alexander G, Safyan, Rachael A, Bates, Susan E, Manji, Gulam A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185320/
https://www.ncbi.nlm.nih.gov/pubmed/32368150
http://dx.doi.org/10.2147/CMAR.S211151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185320/
https://www.ncbi.nlm.nih.gov/pubmed/32368150
http://dx.doi.org/10.2147/CMAR.S211151

Ejemplares similares